At this year’s Community Oncology Conference, new early-phase data from the Community Oncology Alliance’s Quality of Care Study have added to a growing body of evidence challe ...

Targeted Oncology™ is a leading omnichannel resource for community oncologists, offering innovative learning and peer interaction through print and digital platforms. Our custom programs meet your ...

Although PTCy has enabled a surge in mismatched unrelated donor (MMUD) transplantations, its standard administration comes ...

Sabari, MD, discusses dosing, administration, and optimal patient management when using zongertinib to treat patients with ...

Sabari, MD, discusses his personal experience treating patients with zongertinib as part of the Beamion LUNG‑1 trial, which ...

Sabari, MD, discusses exploring combination approaches as the next research step with zongertinib in patients with HER2 ...

FDA orphan drug designation for CLN-049 in R/R AML provides incentives including qualified trial tax credits, certain user-fee waivers, and potential 7-year market exclusivity after approval. Fast ...

A combination regimen targeting LAG-3 and PD-1 did not significantly extend progression-free survival in advanced melanoma vs single-agent pembrolizumab. Fianlimab (REGN3767), a LAG-3 inhibitor, in ...

An evidence gap persists in BCG-unresponsive NMIBC because pivotal approvals rely on single-arm studies, making indirect ...

Financial toxicity is pervasive in rural oncology, with 53% reporting unaffordable care, 50% carrying medical debt, and 70% ...

NIH funding disruptions threaten cancer trial pipelines, stalling early detection and new therapies—what oncologists and ...

The TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) demonstrated a statistically significant ...